Drug Combo Proves Powerful Against Lung Cancer Roosevelt NY

A two-drug combination treatment in Roosevelt proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Abdul G Mundia
(516) 763-1962
2000 N Village Ave
Rockville Centre, NY
Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
NOAH KORNBLUM, MD
(718) 920-4826
111 E 210Th Street
Bronx, NY
HAN XIAO, MD
(908) 542-3300
650 Commack Road
Commack, NY
John Steven Marino, MD
516-883-0122
44 S Bayles Ave
Port Washington, NY
Roy A Debeer
(718) 471-7010
407 Beach 20th St
Far Rockaway, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
SMITHA MELLACHERUVU, MD
(718) 920-4826
111 E 210Th Street
Bronx, NY
Minaxi P Jhawer, MD
111 E 210th St
Bronx, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Roosevelt NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Exercise for Breast Cancer Survival Roosevelt NY
- Fungal Infection Treatments Roosevelt NY
- Exercise for Prostate Cancer Roosevelt NY
- Risks for Childhood Cancer Survivors Roosevelt NY
- Hormone Therapy for Breast Cancer Roosevelt NY
- Genetic Clues for Skin Cancer Therapies Roosevelt NY
- Hormone Therapy for Lung Cancer Roosevelt NY
- Delayed Prostate Cancer Therapy Roosevelt NY